Drawing for NAVICAN PRECISION CANCER CARE

USPTO serial 87468467

NAVICAN PRECISION CANCER CARE

Reviewed by CopyMark Law Group

Reg. 5384399Status 710
Filing date
Status date
Registration date
Jan 23, 2018
Examiner
LEASER, ANDREW C
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with NAVICAN PRECISION CANCER CARE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joshua G. Gigger

JOSHUA G. GIGGER STOEL RIVES LLPONE UTAH CENTER201 SOUTH MAIN STREET, SUITE 1100SALT LAKE CITY, UT 84111

Goods and services

ClassDescriptionStatusFirst use
010Medical specimen collection kits containing a slide cassette and envelope for collection of cells, tissue, blood, urine, other body fluids and fecal matterSECTION 8 - CANCELLEDMay 12, 2017
035Pharmaceutical procurement services, namely, purchasing pharmaceuticals for others; pharmaceutical cost management services and drug utilization review services; assisting patients in enrolling in diagnostics and pharmaceutical reimbursement programs of others; providing business, pricing, reimbursement benchmarking and other market intelligence information in the field of drug reimbursement for prescribers, patients and the pharmaceutical industry; providing business, pricing, reimbursement benchmarking and other market intelligence information in the field of diagnostics reimbursement for providers and patients; business administration of diagnostics and pharmacy reimbursement programs and services; business management and consultation services in the field of specialty pharmacy, namely, assisting patients and providers with pharmaceutical reimbursement; business management and consultation services in the field of off label pharmaceuticals, namely, assisting patients and providers with pharmaceutical reimbursement; business management services in the field of diagnostics, namely, assisting patients and providers with diagnostics reimbursement; promoting collaboration within the scientific, research and medical communities to achieve advances in the fields of healthcare and pharmaceuticals; and business management of comprehensive programs involving drug therapySECTION 8 - CANCELLEDMay 12, 2017
044Dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive treatment programs involving drug therapy; physician support services in the nature of providing consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship, and other related medical information in the field of oncology; providing a database in the field of oncology and featuring inputting and collection of data and information all for treatment and diagnosis purposes; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; and providing an online searchable database in the fields of oncology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancerSECTION 8 - CANCELLEDMay 12, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 2, 2024C8..CANCELLED SEC. 8 (6-YR)—
Jan 23, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Aug 14, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 23, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 7, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 7, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 18, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 1, 2017ALIEASSIGNED TO LIE—
Sep 16, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 26, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Aug 26, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 26, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 26, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 24, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Aug 24, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 24, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 24, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 17, 2017DOCKASSIGNED TO EXAMINER—
Jun 6, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 2, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance